Injection Site Complications: What to Watch For

Anyone who self-administers subcutaneous injections on a repeated schedule, whether for insulin, hormone therapy, or research peptides, will eventually deal with some form of injection site change. Most of these changes are minor: a bit of redness, a small bruise, mild tenderness that resolves in a day or two. But a smaller set of complications, including lipohypertrophy, localized infection, and nerve injury, are worth understanding in more depth because they are directly related to technique and site rotation, and because recognizing early warning signs matters more than most people realize.

This topic matters because self-injection has become far more common outside of hospitals and clinics than it was a generation ago. Insulin-dependent diabetes has long involved daily or multiple-daily self-injection, and that population is where most of the formal injection site research originates. More recently, home-administered hormone therapies and research peptides have expanded the number of people managing their own subcutaneous injection routines without a nurse or clinician present for every dose. The underlying tissue science does not change based on what is in the syringe, but the amount of formal, peptide-specific research on injection site outcomes has not caught up with how widespread self-injection has become, which is part of why this topic is worth covering directly rather than assuming everyone already knows the basics.

Lipohypertrophy is the most common of these complications. It refers to a firm or rubbery lump of fatty tissue that forms under the skin at a site that has been injected repeatedly. It is not dangerous in itself, but it changes the texture of the tissue and can alter how a subsequent injection is absorbed, since scarred or hypertrophic tissue has reduced blood flow compared to healthy fat. Most of what is known about lipohypertrophy comes from the insulin injection literature, where it has been studied for decades. A 2025 systematic review and meta-analysis of insulin infusion therapy found that inadequate site rotation was associated with more than double the odds of lipohypertrophy (pooled odds ratio of 2.59) [1]. Older cohort data found the risk of lipohypertrophy was roughly eight times higher in people who did not rotate sites compared with those who did. This is Moderate Human Evidence for insulin injections specifically; it has not been formally replicated in peptide-injecting populations, though the underlying tissue biology (repeated mechanical and chemical exposure to the same patch of subcutaneous fat) is not unique to insulin.

Localized infection is a separate and more urgent concern. Cellulitis is a bacterial infection of the skin and the tissue just beneath it, usually introduced through a break in the skin barrier, such as a needle puncture. According to the Mayo Clinic, cellulitis typically presents as an area of skin that is swollen, red, warm to the touch, and painful, and it can be accompanied by fever if the infection spreads [3]. Left unaddressed, it can progress into deeper tissue over hours to days. Public health guidance on injection safety, including CDC recommendations on safe injection practice, emphasizes that a new sterile needle and syringe for each injection, along with proper skin preparation, meaningfully reduces the risk of introducing bacteria into the tissue [4]. This is a well-established area of Strong Human Evidence, since safe injection practice has been studied extensively in both clinical and self-injection contexts.

Nerve injury from injection is rare but deserves particular attention because, unlike lipohypertrophy or most localized infections, it can leave permanent effects. A clinical and neurophysiological study of intramuscular injection-related nerve injuries found that the sciatic nerve was the single most commonly affected nerve, followed by the radial nerve, and that despite treatment, only a minority of patients achieved a full recovery [2]. Subcutaneous peptide injections carry a much lower risk profile than intramuscular injections, largely because the needles used are shorter and the injection depth is shallower, but the mechanism is the same: a needle making direct contact with a nerve, or a nerve being compressed by fluid injected too close to it, can cause immediate sharp, shooting, or electric-shock-like sensations. This body of evidence is grounded in clinical case series and cohort data (Moderate Human Evidence for intramuscular injection; more limited data specific to subcutaneous injection).

The mechanisms behind these three complications differ, but the practical prevention strategies overlap substantially. Site rotation, meaning distributing injections across different regions of the abdomen, thighs, and other approved sites rather than reusing the same small patch of skin, is the single most consistently supported measure against lipohypertrophy. Using a new needle for each injection, rather than reusing a needle that has already dulled, reduces both tissue trauma and the chance of introducing bacteria, since a duller needle requires more force and causes more disruption to the surrounding tissue on entry. Allowing topical antiseptic to dry on the skin before inserting the needle is also part of standard injection safety guidance, since antiseptics require a period of contact time to reduce bacterial load on the skin surface [4].

Needle gauge and length are part of the same picture. Fine-gauge, short insulin-style needles are designed specifically for the subcutaneous layer rather than muscle, and CDC injection safety guidance treats a fresh, single-use needle and syringe for every injection as a baseline standard rather than an optional precaution [4]. A needle that has already been used loses sharpness, which increases the force required to penetrate the skin and correspondingly increases local tissue disruption. None of this eliminates the need for individualized guidance from a pharmacist or clinician about the specific supplies appropriate for a given injection routine, but it does explain, mechanistically, why single-use needles and rotation are emphasized so consistently across the injection safety literature rather than treated as minor details.

There is meaningful uncertainty in this space that is worth naming directly. Much of the strongest human evidence on lipohypertrophy and rotation technique comes from insulin-dependent diabetes research, a population injecting multiple times a day over years or decades. It is reasonable to expect similar mechanisms apply to other subcutaneous injection routines, but the frequency, volume, and formulation of research peptide injections differ from insulin therapy in ways that have not been directly studied. There is also no large-scale, peptide-specific dataset tracking injection site complication rates, so estimates of how common these problems are in that population are necessarily extrapolated rather than directly measured. Individual variation in technique, needle gauge, injection depth, and skin condition further complicates any attempt to give a single, universal risk estimate.

A related open question is what to do when a specific injection site continues to react poorly despite good rotation habits and correct technique. There are several plausible contributing factors: the compound itself, an excipient such as a preservative in the diluent, an impurity introduced during handling or storage, or simple individual sensitivity that has nothing to do with technique at all. The available literature does not cleanly separate these possibilities for most research peptides, since formal post-market surveillance of this kind does not exist the way it does for approved pharmaceuticals. This is a genuine gap rather than a settled question, and it is one of the clearest examples of why peptide-specific research safety information lags behind decades of insulin and injectable-medication research.

In terms of what this means practically, minor and temporary redness, small bruising, or mild soreness after an injection is common and not typically a cause for concern on its own. Signs that generally warrant prompt medical evaluation, according to public health and clinical sources, include: spreading redness or warmth that expands beyond the immediate injection area, especially if it spreads over hours; fever in combination with a red or swollen injection site; a firm, painful, fluid-filled lump that does not resolve within a few days; or any sharp, shooting, burning, or electric sensation during an injection, which should prompt stopping the injection immediately rather than continuing. None of this is a substitute for individualized medical guidance, and anyone experiencing concerning symptoms at an injection site should seek evaluation from a qualified clinician rather than attempting to self-manage what could be an infection or nerve involvement. The general prevention principles, consistent site rotation, single-use needles, and adequate antiseptic contact time, are well supported by the injection safety literature, even where peptide-specific data remains thin [1][2][3][4].

Read together, the evidence base here is uneven by design rather than by oversight. Injection safety and needle-stick practice sit on Strong Human Evidence built from decades of clinical infection-control research. Lipohypertrophy prevention through site rotation sits on Moderate Human Evidence drawn mostly from insulin-injecting populations. Nerve injury from injection is documented through case series and cohort studies rather than large controlled trials, which places it closer to Moderate Human Evidence for intramuscular injection specifically, with materially less direct data for subcutaneous routes. None of these categories should be read as reassurance that a given individual's risk is low or high; they describe how confident the underlying research community can be in the general pattern, not what will happen in any specific case.